Actualités et Activités de Affini-T Therapeutics
Dirigeants
Voir l'organigramme avec ses 9 principaux dirigeants
Biographies les plus recherchées chez Affini-T Therapeutics
- Jak Knowles, Co-Founder, President, Chief Executive Officer and D...
- Helen Kim, Director
- Jill Desimone, Director
Changements de dirigeants chez Affini-T Therapeutics
- Loïc Vincent, Chief Scientific Officer, a quitté l'entreprise (publié le 2 avril 2025).
- Loïc Vincent, Chief Scientific Officer, a quitté l'entreprise (publié le 2 avril 2025).
Créer une alerte
pour suivre les mouvements de dirigeants chez Affini-T Therapeutics.
Biotechnologie
Affini-T Therapeutics a 2 350 concurrents dont Eurofins (Luxembourg), Lonza (Suisse) et Genus (Royaume—Uni).
Actualités en fusion/acquisition en Biotechnologie.
- Transcarent and Accolade have merged (publié le 9 avril 2025)..
- Kashiv BioSciences vient d'annoncer une levée de fonds de 150 millions de dollars. (publié le 7 avril 2025).
- Atsena Therapeutics vient d'annoncer une levée de fonds de 150 millions de dollars. (publié le 4 avril 2025).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Affini-T Therapeutics
- Affini-T Therapeutics to Present Trial-in-Progress Poster and Preclinical Data from Its Oncogenic Driver Programs Targeting TP53 R175H, KRAS G12D and KRAS-G12V at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics Announces First Patient Dosed in KRAS G12V Phase 1 Program and Presentation of Trial-in-Progress Poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics to Present Data from Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024 | Affini-T Therapeutics
- Affini-T Therapeutics to Present Preclinical Data from its Programs Targeting KRAS G12D and p53 R175H and Two Trials in Progress at the American Association for Cancer Research (AACR) Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | Affini-T Therapeutics
- Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer | Affini-T Therapeutics
- Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations - Affini-T Therapeutics
- Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations - Affini-T Therapeutics
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Affini-T Therapeutics
- Affini-T Therapeutics sur Wikipédia, Google News & Yahoo Finance en 1-click
- Affini-T Therapeutics sur LinkedIn, Twitter & YouTube en 1-click
